Oncology Integrations
Order and manage both germline and tumor genomic tests right inside the EMR platform you already use. Fewer steps, faster turnaround, concordant results, and no more juggling multiple labs or tracking down fragmented reports.
With our comprehensive oncology-focused portfolio, expanding your Myriad Oncology ordering in OncoEMR isn’t just easier—it’s better for you and your patients.
All-in-one ordering
Seamlessly order MyRisk® Hereditary Cancer Test, Precise Tumor® Molecular Profile Test, MyChoice® CDx HRD Myriad HRD Companion Diagnostic Test, and immunohistochemistry (IHC) testing for PD-L1 and Folate receptor alpha (FOLR1/FRα) in a single workflow.
Concordant results
With Myriad Oncology, you get concordant results across the entire patient journey, avoiding inconsistencies that arise when multiple labs interpret variants differently.
One-page summary
You’ll receive clear, clinically actionable insights delivered directly to your EMR, along with a treatment-focused summary sheet consolidating germline and tumor genomic information on a single page that is easy to read and easy to share with patients.
Faster turnaround
Speed up turnaround times and increase visibility across your care team. No more switching between portals and paper Test Requisition Forms (TRFs). No more juggling multiple labs or tracking down fragmented reports.
Guideline adherence
With ASCO recommending germline testing for all eligible patients regardless of tumor results, Myriad simplifies adherence to these guidelines, helping to ensure that no critical variant or therapy opportunity is missed.1
Myriad can support most EMR platforms you currently use. We offer native integration with most EMR platforms and can build customizable solutions for others.
Coming soon
With Myriad Oncology, results are clear, treatment-focused, and clinically-actionable—making it easier to personalize therapy decisions, identify clinical trials, and support patients with confidence, across the entire patient journey.
By choosing Myriad Oncology, you also get access to our unrivaled suite of services—from pre- and post-test education to billing and clinical support—at no added cost to your clinic or patients.
The MyRisk Test provides more answers for more patients by identifying up to 63% of variants other labs cannot definitively classify and offers the industry’s lowest reported rates of BRCA1/2 variants of uncertain significance (VUS) of 1.0%.2,3
The Precise Test utilizes combined DNA and RNA sequencing to detect more fusion and splice variants compared to DNA-only tests, increasing patient eligibility for targeted therapies and clinical trials.4-7
The MyChoice CDx test helps you expand access to PARP inhibitors by identifying 34% more HRD-positive ovarian cancer patients than other tests that only use %LOH.8
The Prolaris Test combines genomic (CCP) and clin-path features to provide results as early as your patient’s first cancer consultation and determines how aggressive the cancer is behaving.
For customers who use OncoEMR in their practice, we have created a step-by-step video guide for you and your staff that walks through how to order the appropriate tests in the OnocEMR system.
Yes - when you order combined testing through OncoEMR, you will continue to receive a treatment-focused results summary sheet. You’ll also continue to have access to Myriad’s full suite of complimentary services, including pre-and post-test education, billing support, and more.
Once the test has been submitted within OncoEMR, the test status will only change after the result is reported. Customer service or lab processing updates will be available through the portal. (Note: once the sample is received at the lab, the test information will usually be available in the portal within 48 hours.)
No - enter the order and click submit in OncoEMR only. Results should be visible both directly in the medical record and within the Myriad provider portal.
Please contact your local Myriad representative for assistance.
Yes.
Yes - this can be achieved by setting up a group inbox.
Yes - you can order STAT testing for breast, pancreatic, and colorectal cancer patient cases. Make sure to place the pink STAT sticker on the outside of the FedEx bag and type “STAT” in the free text/notes section of the order.
You can include multiple tumor tests in one order, but only one germline test can be ordered at a time. (Note: the BRACAnalysis Test is ordered for patients meeting hereditary breast and ovarian cancer syndrome criteria, while the COLARIS Test is ordered for patients meeting Lynch syndrome or MUTYH-associated polyposis (MAP) criteria. Include the MyRisk Update test for analysis of additional hereditary cancer genes excluding those listed.)
Results are returned to the provider’s inbox under the category that the practice has configured Molecular Profiling Integration (MPI) results to return (defaults to Pathology). Results can also be accessed from the Documents tab or from the Treatment Plan.
Yes - from the test result hyperlink (in Documents, Treatment Plan page, or Other folder).
Yes - the provider will be notified that a new result is available to be reviewed.
Yes - the results from orders submitted on paper or in the Myriad provider portal will NOT be reported in OncoEMR.
Yes - including the clinic note upfront with the order will aid in timely processing, insurance authorization, and release of the test. Including the clinic note in the order will also reduce the likelihood of the lab contacting the provider for additional details, potentially improving turnaround times.
Yes - you can place a future order as long as the surgery date (i.e., the specimen collection date) is within 30 days from today. Be sure to include contact information for the pathology department responsible for submitting the tumor sample. Myriad Customer Service will set a reminder to follow up the day after the scheduled surgery. If the surgery date changes, please notify Myriad as soon as possible.
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
References: